市場調查報告書
商品編碼
1320992
內分泌檢測市場 - 按測試類型(人絨毛膜促性腺激素 (hCG) 激素測試、胰島素測試)、按技術(質譜、免疫分析)、按最終用途(醫院、臨床實驗室)和預測,2023 - 2032 年Endocrine Testing Market - By Test Type (Human Chorionic Gonadotropin (hCG) Hormone Test, Insulin Test), By Technology (Mass Spectroscopy, Immunoassay), By End-use (Hospitals, Clinical Laboratories) & Forecast, 2023 - 2032 |
全球內分泌檢測市場將在 2023 年至 2032 年間出現顯著成長。
全球老年人口的持續成長將推動未來十年的行業成長。據世界衛生組織稱,到2050年,60歲以上的人口將佔世界人口的22%。老年人更容易患內分泌疾病,如糖尿病、甲狀腺功能障礙和腎上腺疾病,需要準確的診斷測試,從而為市場拓展做出貢獻。診斷技術的技術進步和創新內分泌檢測產品的推出也在推動市場成長方面發揮著至關重要的作用。此外,個人對預防保健和早期疾病檢測的認知不斷增強,推動了內分泌檢測的採用,從而推動了市場收入。
整體內分泌檢測市場佔有率根據測試、技術、最終用途和地區進行分類。
就測試而言,到 2032 年,胰島素細分市場有望佔據相當大的市場佔有率。對胰島素測試的需求主要是由全球糖尿病患病率不斷上升推動的。根據 CDC 2022 年國家糖尿病統計報告,估計美國有 1.3 億成年人患有糖尿病或糖尿病前期。隨著糖尿病病例持續增加,準確測量胰島素水準對於有效的疾病管理和個性化治療計劃至關重要。胰島素測試在診斷糖尿病、監測治療效果和預防併發症方面發揮著關鍵作用,導致對此類測試的持續需求。
在技術方面,到2032年,色譜領域的內分泌檢測行業規模將以顯著的年複合成長率擴大。色譜檢測高度靈敏和準確,可以同時分析多種激素。該技術可有效分離和檢測複雜的激素混合物,有助於精確診斷和監測內分泌失調。對可靠和全面的診斷方法不斷成長的需求正在推動內分泌學領域採用基於色譜的測試。
預計到 2032 年,診斷中心將成為內分泌檢測的主要最終用戶。內分泌疾病的患病率不斷增加,加上人口老齡化,迫切需要準確、及時的激素評估。此外,檢測技術的進步使內分泌檢測變得更加容易,從而在診斷中心得到更高的採用,從而能夠及早發現和有效管理內分泌相關疾病。
到 2032 年,歐洲內分泌檢測行業將錄得可觀收入。該地區人口老齡化導致內分泌疾病患病率更高,從而增加了對綜合檢測的需求。此外,人們對預防保健和早期疾病檢測的認知不斷提高,推動了對內分泌檢查的需求,有助於及時干涉和治療。診斷技術的進步也使內分泌檢測變得更加容易,進一步推動了其在歐洲的普及。
Global Endocrine Testing Market will register significant growth between 2023 and 2032.
The consistent rise in the geriatric population worldwide will drive industry growth over the next ten years. According to WHO, people aged over 60 years will account for 22% of the world's population by 2050. Aging people have a greater susceptibility to endocrine disorders, such as diabetes, thyroid dysfunction, and adrenal gland disorders, that require accurate diagnostic tests, thereby contributing to market expansion. Technological advancements in diagnostic techniques and the introduction of innovative endocrine testing products are also playing a crucial role in fueling market growth. Moreover, the growing awareness among individuals regarding preventive healthcare and early disease detection is propelling the adoption of endocrine testing, driving market revenues.
The overall endocrine testing market share is categorized based on test, technology, end-use, and region.
Regarding the test, the insulin segment is poised to capture a decent market share by 2032. The demand for insulin tests is primarily driven by the escalating prevalence of diabetes worldwide. According to CDC 2022 National Diabetes Statistics Report, an estimated 130 million adults in the US are living with diabetes or prediabetes. As diabetes cases continue to rise, the need to accurately measure insulin levels becomes essential for effective disease management and personalized treatment plans. Insulin tests play a critical role in diagnosing diabetes, monitoring treatment efficacy, and preventing complications, contributing to the sustained demand for such tests.
In terms of technology, the endocrine testing industry size from the chromatography segment will expand at a notable CAGR through 2032. Chromatography testing is highly sensitive and accurate and can analyze multiple hormones simultaneously. This technique offers efficient separation and detection of complex hormone mixtures, aiding in precise diagnosis and monitoring of endocrine disorders. The growing demand for reliable and comprehensive diagnostic methods is propelling the adoption of chromatography-based testing in the field of endocrinology.
Diagnostic centers are anticipated to emerge as a prominent end-user for endocrine testing by 2032. The increasing prevalence of endocrine disorders, coupled with the aging population, drives the need for accurate and timely hormone assessments. Moreover, advancements in testing technologies have made endocrine assays more accessible, leading to higher adoption in diagnostic centers, enabling early detection and effective management of endocrine-related conditions.
Europe endocrine testing industry will record significant revenue through 2032. The region's aging population contributes to a higher prevalence of endocrine disorders, increasing the need for comprehensive testing. Additionally, rising awareness about preventive healthcare and early disease detection fuels the demand for endocrine tests, aiding in timely intervention and treatment. Advances in diagnostic technologies also make endocrine testing more accessible, further driving its popularity in Europe.